Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference businesswire.com/news/home/2024…

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at #JPMHC24 Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2'24 businesswire.com/news/home/2024…

Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference Summit scheduled to present on Wednesday, February 14, 2024, at 2:40PM ET businesswire.com/news/home/2024…

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 Conference Call to be Held at 9:00am ET businesswire.com/news/home/2024…

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference Presentation is scheduled for Tuesday March 12, 2024 at 2:35pm ET businesswire.com/news/home/2024…

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 businesswire.com/news/home/2024…

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com/news/home/2024…

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 Conference Call to be Held at 9:00am ET businesswire.com/news/home/2024…

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 HARMONi and HARMONi-3 Enrollment Continues Updated Guidance of Cash Runway for Operations through Q1 2025 businesswire.com/news/home/2024…

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China businesswire.com/news/home/2024…

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy businesswire.com/news/home/2024…

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA businesswire.com/news/home/2024…

Summit Raises $200 Million at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa businesswire.com/news/home/2024…

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors businesswire.com/news/home/2024…

Summit Therapeutics and MD Anderson (MD Anderson Cancer Center) Announce Strategic Collaboration to Accelerate Development of Ivonescimab Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials businesswire.com/news/home/2024…

We are excited to begin our collaboration with MD Anderson Cancer Center to accelerate the development of ivonescimab

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at #WCLC24 Additionally, Ivonescimab Phase II Data in Perioperative Setting for Resectable NSCLC to be Presented at IASLC's World Lung businesswire.com/news/home/2024…

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China businesswire.com/news/home/2024…

Summit Therapeutics $SMMT shares nearly doubling this week after its lung cancer drug beat Merck's Keytruda in a head-to-head trial. Summit Therapeutics CEOs Bob Duggan and Maky Zanganeh explain what's ahead for the treatment, and the potential impact of the BIOSECURE Act.

Summit Therapeutics Raises $235 Million Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at Sept 11 2024 Closing Price of $22.70 businesswire.com/news/home/2024…